<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04556032</url>
  </required_header>
  <id_info>
    <org_study_id>MB-2011</org_study_id>
    <nct_id>NCT04556032</nct_id>
  </id_info>
  <brief_title>Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women</brief_title>
  <official_title>A Placebo-controlled, Randomized, Double-blind Trial to Assess the Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Midwest Center for Metabolic and Cardiovascular Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Blue California Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Midwest Center for Metabolic and Cardiovascular Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the effects of ergothioneine at two doses, compared&#xD;
      to placebo, on cognition, mood, and sleep in healthy adult men and women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a placebo-controlled, randomized, double-blind, parallel-arm trial. The study&#xD;
      will consist of one screening (visit 1a, week 0), one baseline visit (visit 1b, week 0), and&#xD;
      three treatment visits (visits 2, 3, and 4; weeks 4, 8, and 16).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor terminated study due to unforeseen recruitment circumstances amidst the COVID19&#xD;
    pandemic.&#xD;
  </why_stopped>
  <start_date type="Actual">September 9, 2020</start_date>
  <completion_date type="Actual">October 30, 2020</completion_date>
  <primary_completion_date type="Actual">October 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the composite memory standard score from the Central Nervous System Vital Signs (CNS-VS) Test Battery</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the composite memory standard score from the Central Nervous System Vital Signs (CNS-VS) Test Battery</measure>
    <time_frame>Baseline to weeks 4 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in standard scores for domains relating to memory, attention, and executive function from the Central Nervous System Vital Signs (CNS-VS) Test Battery</measure>
    <time_frame>Baseline to weeks 4, 8 and 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in sleep quality based on Leeds Sleep Evaluation Questionnaire (LSEQ)</measure>
    <time_frame>Baseline to weeks 4, 8 and 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in mood based on Profile of Mood States Questionnaire (POMS)</measure>
    <time_frame>Baseline to weeks 4, 8 and 16</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>L-Ergothioneine 10 mg/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive L-Ergothioneine 10 mg capsule orally once daily for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L-Ergothioneine 25 mg/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive L-Ergothioneine 25 mg capsule orally once daily for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo orally once daily for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-Ergothioneine 10 mg/d</intervention_name>
    <description>L-Ergothioneine 10 mg/d</description>
    <arm_group_label>L-Ergothioneine 10 mg/d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-Ergothioneine 25 mg/d</intervention_name>
    <description>L-Ergothioneine 25 mg/d</description>
    <arm_group_label>L-Ergothioneine 25 mg/d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0 mg/d L-Ergothioneine</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals 55-79 years of age.&#xD;
&#xD;
          -  Body mass index (BMI) 18.50-34.99 kg/m2&#xD;
&#xD;
          -  Non-smoker defined as no smoking for at least 6 months.&#xD;
&#xD;
          -  Willing to limit alcohol and caffeine consumption&#xD;
&#xD;
          -  Generally, in good health based on medical history and laboratory assessments&#xD;
&#xD;
          -  Agree to avoid consumption of mushrooms and excluded medications/supplements for the&#xD;
             duration of the study&#xD;
&#xD;
          -  Willing to commit to all study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Consumption of mushrooms more than once per week&#xD;
&#xD;
          -  History or presence of a psychiatric or neurologic disease including, but not limited&#xD;
             to, epilepsy, cerebrovascular disturbance, traumatic injury, or clinically diagnosed&#xD;
             dementia or Alzheimer's disease.&#xD;
&#xD;
          -  Scores â‰¥17 on the Beck Depression Inventory&#xD;
&#xD;
          -  History of cardiovascular complications, type 1 or type 2 diabetes mellitus,&#xD;
             uncontrolled hypertension, or any other clinically significant disorder&#xD;
&#xD;
          -  History of cancer except non-melanoma skin cancer or carcinoma in situ of the cervix&#xD;
             within the past 2 years&#xD;
&#xD;
          -  Use of any product containing marijuana (THC) and/or cannabidiol (CBD) including oral&#xD;
             consumption, inhalation, &amp; other&#xD;
&#xD;
          -  Any intolerance to any components of the study products&#xD;
&#xD;
          -  Exposure to any non-registered drug product within the past 30 days&#xD;
&#xD;
          -  History of drug or alcohol abuse&#xD;
&#xD;
          -  Considered unfit for any reason as determined by the principal investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Great Lakes Clinical Trials</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 9, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ergothioneine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

